A meta-analysis study in the diagnostic accuracy of anti-GPL core IgA in MAC pulmonary diseases (MAC-PD) indicated 69.6% (95% CI 62.1–76.1%) sensitivity and 90.6% (95% CI 83.6–95.1) specificity [20]. Here, CD79A is linked to lung disorder.